This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic

This study has been completed.
Information provided by:
Sodilac Identifier:
First received: June 26, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
The purpose of this study is to evaluate the nutritional adequacy, the digestive tolerance and the effect on colic of an alpha-lactalbumin-enriched and probiotic-supplemented infant formula.

Condition Intervention Phase
Growth Colic Other: Modilac Dahlia 1 Other: Modilac 1 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Study of Growth and Gastrointestinal Tolerance of an Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic.

Resource links provided by NLM:

Further study details as provided by Sodilac:

Primary Outcome Measures:
  • Crying duration per 24 hours [ Time Frame: 1 day before the first consumption ; 3 days before days 15 and 30 ]

Secondary Outcome Measures:
  • Growth Parameters [ Time Frame: Day 30 ]
  • Clinical Tolerance [ Time Frame: 3 days before days 15 and 30 ]
  • Number of therapeutic failures (no diminution in the intensity or the frequency of the digestive symptoms) [ Time Frame: Durind the 15 first days of the diet and during the 15 last days of the diet ]
  • Number of regurgitations per day [ Time Frame: 3 days before days 15 and 30 ]
  • Gas and abdominal distensions [ Time Frame: 3 days before days 15 and 30 ]
  • Necessary Additive treatments [ Time Frame: 3 days before days 15 and 30 ]
  • Parents' satisfaction [ Time Frame: Days 15 and 30 ]
  • Agitation/Restlessness Period Duration [ Time Frame: 3 days before days 15 and 30 ]

Enrollment: 66
Study Start Date: November 2006
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Modilac Dahlia 1
Formula enriched with alpha-lactalbumin and containing a probiotic
Other: Modilac Dahlia 1
Infant formula used for non breastfed children with colic
Other Name: Dahlia
Placebo Comparator: Modilac 1
Regular milk
Other: Modilac 1
Infant formula used for non breastfed children
Other Name: Modilac

Detailed Description:

This double-blind, placebo-controlled study was undertaken with 66 healthy infants with colic, aged 3 weeks to 3 months, fed a month either with the experimental formula (EF) or with the control formula (CF) and evaluated for efficacy and safety parameters at days 15 and 30.

Both parents provided informed written consent.


Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy term infants with a gestational age ranging from 37 to 42 weeks
  • Non breastfed children
  • Infants with normal growth
  • Infants presenting colic defined as crying periods at least 3 hours per days, 3 days per weeks, for more than 3 weeks
  • These crying periods could be associated with other digestive troubles(gas, abdominal distensions, regurgitations)
  • Apgar score > 5 to 7 minutes

Exclusion Criteria:

  • Infants with severe regurgitations
  • Newborn currently participating in another trial
  • Infants presenting a metabolic, nervous or organic disease able to interfere with the study
  • Infants presenting lactose intolerance
  • Evidence of protein cow's milk allergy
  • Mother who wants to keep breasfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00929292

Dr Francine Gressin-Cohen
Antony, France, 92160
Hôpital privé d'Antony
Antony, France, 92166
Hôpital Robert Ballanger
Aulnay sous Bois, France, 93602
Dr Brigitte Pacault
Boulogne Billancourt, France, 92100
Dr Michel Dogneton
Boulogne Billancourt, France, 92100
Dr Nassira Belaroussi Maamri
Boulogne Billancourt, France, 92100
Issy-les-Moulineaux, France, 92130
Groupe Hospitalier de l'Institut Catholique de Lille (GHICL)
Lille, France, 59020
Dr Christophe Grillon
Meaux, France, 77100
Paris, France, 75013
Dr RONZIER Monique
Paris, France, 75015
Dr Locquet André
Roncq, France, 59223
Sponsors and Collaborators
Principal Investigator: Christophe Dupont, PhD Hôpital Saint Vincent de Paul
  More Information

Responsible Party: Pr Christophe Dupont, Hôpital Saint Vincent de Paul Identifier: NCT00929292     History of Changes
Other Study ID Numbers: DAH-CL3-001
Study First Received: June 26, 2009
Last Updated: June 26, 2009

Keywords provided by Sodilac:
Infant formula
Protein composition

Additional relevant MeSH terms:
Infant, Newborn, Diseases processed this record on August 17, 2017